MX2022014099A - Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado. - Google Patents

Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado.

Info

Publication number
MX2022014099A
MX2022014099A MX2022014099A MX2022014099A MX2022014099A MX 2022014099 A MX2022014099 A MX 2022014099A MX 2022014099 A MX2022014099 A MX 2022014099A MX 2022014099 A MX2022014099 A MX 2022014099A MX 2022014099 A MX2022014099 A MX 2022014099A
Authority
MX
Mexico
Prior art keywords
gamma
compositions
treating
preventing
methods
Prior art date
Application number
MX2022014099A
Other languages
English (en)
Inventor
John Rathmacher
Naji Abumrad
Charles Flynn
Original Assignee
Mti Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mti Biotech Inc filed Critical Mti Biotech Inc
Publication of MX2022014099A publication Critical patent/MX2022014099A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos y composiciones para el uso en tratar, atenuar, prevenir o mejorar fibrosis de hígado en un sujeto. Los compuestos de la presente invención son depuradores de gamma-cetoaldehído.
MX2022014099A 2017-09-05 2020-03-03 Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado. MX2022014099A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762554294P 2017-09-05 2017-09-05

Publications (1)

Publication Number Publication Date
MX2022014099A true MX2022014099A (es) 2022-12-08

Family

ID=65634496

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002441A MX2020002441A (es) 2017-09-05 2018-09-05 Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado.
MX2022014099A MX2022014099A (es) 2017-09-05 2020-03-03 Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020002441A MX2020002441A (es) 2017-09-05 2018-09-05 Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado.

Country Status (9)

Country Link
US (1) US20190099387A1 (es)
EP (1) EP3678650A4 (es)
JP (1) JP7441170B2 (es)
CN (1) CN111225666A (es)
AU (1) AU2018330416A1 (es)
BR (1) BR112020004372A2 (es)
CA (1) CA3074736A1 (es)
MX (2) MX2020002441A (es)
WO (1) WO2019050967A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018048932A1 (en) * 2016-09-06 2018-03-15 Metabolic Technologies, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1181871B (it) * 1985-04-01 1987-09-30 Consiglio Nazionale Ricerche Inibitori selettivi delle benzilamminossidasi rispetto ad altre amminossidasi
CN103796648B (zh) * 2011-07-12 2019-10-25 范德比尔特大学 用γ-醛酮清除剂治疗炎症和高血压的方法
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
WO2018048932A1 (en) * 2016-09-06 2018-03-15 Metabolic Technologies, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Also Published As

Publication number Publication date
EP3678650A4 (en) 2021-05-19
JP7441170B2 (ja) 2024-02-29
EP3678650A1 (en) 2020-07-15
BR112020004372A2 (pt) 2020-09-08
WO2019050967A1 (en) 2019-03-14
AU2018330416A1 (en) 2020-04-02
US20190099387A1 (en) 2019-04-04
CA3074736A1 (en) 2019-03-14
MX2020002441A (es) 2020-09-03
CN111225666A (zh) 2020-06-02
JP2020532591A (ja) 2020-11-12

Similar Documents

Publication Publication Date Title
MX2018015761A (es) Composiciones que comprenden cepas bacterianas.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
JOP20210060A1 (ar) معدلات لمضاد تريبسين ألفا-1
IL272844A (en) Compounds, preparations and methods for the treatment or prevention of cancers resistant to HER-motor drugs
EP3634424A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS
IL285302A (en) Compounds, preparations and methods
WO2015120062A3 (en) Therapeutic compounds and compositions
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
PH12017501864A1 (en) Compositions and methods for treating autism
EP3847283A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER INDUCED CANCERS
IL285886A (en) Preparations and methods for the treatment of laminopathy
ZA202101342B (en) Compositions and methods for treating the eye
ZA202102702B (en) Synergistic disinfectant compositions having enhanced antimicrobial efficacy and stability, and methods of using the same
ZA202107499B (en) Compounds, compositions and methods
MX2018003301A (es) Inhibidores de pcna.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
GB2543723A (en) Polyphenol compositions
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
ZA202007183B (en) Compositions and methods for treating the eye